Lung cancer-associated antigen (LCAA)

Lung cancer-associated antigens (LCAAs) are a heterogeneous group of proteins that are either uniquely expressed or significantly overexpressed in lung cancer cells compared to normal tissues (National Cancer Institute, 2023). This category includes various molecular types such as cancer-testis antigens (e.g., NY-ESO-1, MAGE-A3), oncofetal antigens (e.g., Carcinoembryonic antigen), and overexpressed self-antigens like MUC1 (Journal of Thoracic Oncology, 2021). In clinical oncology, these antigens serve as primary targets for therapeutic cancer vaccines and adoptive T-cell therapies designed to overcome immune tolerance and stimulate a robust anti-tumor response (PubMed, PMID: 25605610). While individual antigens within this group have distinct biological roles—ranging from cell-cell adhesion to signal transduction—their collective therapeutic utility lies in their ability to act as specific markers for immune-mediated destruction of malignant cells. Drugs targeting these antigens, such as Belagenpumatucel-L or TG4010, typically function by enhancing the presentation of these molecules to the immune system or by utilizing them as homing signals for targeted delivery (Clinical Cancer Research, 2015). However, because this term refers to a broad class of molecules rather than a single specific receptor or enzyme, it is often considered a collective target category in drug development databases.

Other names

Tumor-associated antigensLung tumor antigensLung cancer antigensTAA

Stimulation of the host immune system to recognize and destroy tumor cells by presenting specific protein fragments to T-cells or inducing antibody production against these antigens.